Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1B/2 Study of Lurbinectedin With or Without Irinotecan for Patients With Relapsed or High Risk Chemotherapy-Naive Ewing Sarcoma

Next Previous
X
Search
Trial Profile

Phase 1B/2 Study of Lurbinectedin With or Without Irinotecan for Patients With Relapsed or High Risk Chemotherapy-Naive Ewing Sarcoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Lurbinectedin (Primary)
  • Indications Ewing's sarcoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 01 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment as PI stated trial no longer fits the framework & portfolio of work that is prioritized by the department. PI will not have the anticipated accrual in PI view to complete the study. Given that, PI request this protocol be closed prior to its activation.
    • 17 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top